The global US therapeutic plasma exchange market in terms of revenue was estimated to be worth $178 million in 2020 and is poised to reach $243 million by 2025, growing at a CAGR of 6.3% from 2020 to 2025. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

Growth in this market is driven by the rising prevalence of chronic diseases and technological advancements. However, factors such as the high cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model are expected to restrain the growth of this market to a certain extent during the forecast period.

Key players in the US therapeutic plasma exchange market:

The prominent players in the US therapeutic plasma exchange market Terumo BCT, Inc. (US), Fresenius SE Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Miltenyi Biotec (Germany), Medica S.p.A. (Italy), Medicap Clinic GmbH (Germany), and Infomed (Switzerland).

Download the PDF Brochure at https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=87153046

Consumables segment to witness the highest growth during the forecast period

Based on products, the US therapeutic plasma exchange market has been segmented into devices and consumables. The consumables segment witness the highest growth during the forecast period. The fastest growth of this segment can be attributed to the recurrent use of these products, the increasing number of therapeutic plasma exchange procedures, and favorable reimbursement policies for TPE procedures.

The centrifugation segment is expected to account for the largest share of the US therapeutic plasma exchange market in 2019

On the basis of technology, the US therapeutic plasma exchange market has been segmented into centrifugation and membrane separation. In 2019, the centrifugation technology segment accounted for the largest share of the US therapeutic plasma exchange market. The large share of this segment can be attributed to the advantages offered by centrifugation over membrane separation, such as high efficiency and its ability to separate all types of blood components.

Neurological segment to witness the highest growth during the forecast period

On the basis of indication, the US therapeutic plasma exchange market has been segmented into neurological disorders, renal disorders, hematologic disorders, metabolic disorders, and other indications.

In 2019, the neurological disorders segment accounted for the largest share of the US therapeutic plasma exchange market.  Growth in this market is majorly driven by the rising prevalence and incidence of neurological diseases in the geriatric population, increasing awareness about the treatment of neurological diseases using plasma exchange, and rising investments by key players for RD on the new application areas of therapeutic plasma exchange in the treatment of neurological disorders.

The blood collection centers and blood component providers segment is expected to account for the largest share of the US therapeutic plasma exchange market in 2019

Direct Purchase at https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=87153046

On the basis of end users, the US therapeutic plasma exchange market has been segmented into blood

collection centers and blood component providers, hospitals and transfusion centers, and other end users. In 2019, the blood collection centers and blood component providers segment accounted for the largest share of the US therapeutic plasma exchange market. The large share of this end-user segment is mainly attributed to the rising number of blood component donations, the growing number of blood centers, and the increasing number of therapeutic plasma exchange procedures and plasma donations due to COVID-19.